KR101927859B1 - Method for improving the stability and coating efficiency of probiotics using ultrasonic wave after freeze-drying and food composition containing freeze-dried powder of probiotics prepared thereby as effective component - Google Patents
Method for improving the stability and coating efficiency of probiotics using ultrasonic wave after freeze-drying and food composition containing freeze-dried powder of probiotics prepared thereby as effective component Download PDFInfo
- Publication number
- KR101927859B1 KR101927859B1 KR1020180082927A KR20180082927A KR101927859B1 KR 101927859 B1 KR101927859 B1 KR 101927859B1 KR 1020180082927 A KR1020180082927 A KR 1020180082927A KR 20180082927 A KR20180082927 A KR 20180082927A KR 101927859 B1 KR101927859 B1 KR 101927859B1
- Authority
- KR
- South Korea
- Prior art keywords
- lactobacillus
- probiotics
- survival rate
- bifidobacterium
- probiotic
- Prior art date
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 207
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 207
- 239000011248 coating agent Substances 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 48
- 238000000576 coating method Methods 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 235000013305 food Nutrition 0.000 title claims abstract description 14
- 239000000843 powder Substances 0.000 title abstract description 36
- 238000004108 freeze drying Methods 0.000 title abstract description 20
- 239000008176 lyophilized powder Substances 0.000 claims abstract description 49
- 238000002604 ultrasonography Methods 0.000 claims abstract description 36
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 230000001965 increasing effect Effects 0.000 claims abstract description 19
- 230000000529 probiotic effect Effects 0.000 claims description 65
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 35
- 239000012141 concentrate Substances 0.000 claims description 34
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 31
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 31
- 241001608472 Bifidobacterium longum Species 0.000 claims description 26
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 22
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 18
- 241000186660 Lactobacillus Species 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 14
- 229940039696 lactobacillus Drugs 0.000 claims description 14
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 13
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 13
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 13
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 13
- 235000015140 cultured milk Nutrition 0.000 claims description 12
- 235000020510 functional beverage Nutrition 0.000 claims description 11
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 10
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 9
- 241000186012 Bifidobacterium breve Species 0.000 claims description 9
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 9
- 244000199866 Lactobacillus casei Species 0.000 claims description 9
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 9
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 9
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 9
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 9
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 8
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 8
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 4
- 244000057717 Streptococcus lactis Species 0.000 claims description 4
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 4
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 4
- 229940017800 lactobacillus casei Drugs 0.000 claims description 4
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 208000001613 Gambling Diseases 0.000 claims 3
- 235000020299 breve Nutrition 0.000 claims 3
- 230000004083 survival effect Effects 0.000 abstract description 114
- 238000009210 therapy by ultrasound Methods 0.000 abstract description 31
- 238000002156 mixing Methods 0.000 abstract description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 235000008504 concentrate Nutrition 0.000 description 25
- 238000012360 testing method Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 238000012258 culturing Methods 0.000 description 14
- 230000008569 process Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 238000013112 stability test Methods 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 238000007710 freezing Methods 0.000 description 9
- 230000008014 freezing Effects 0.000 description 9
- 230000006353 environmental stress Effects 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 241000186610 Lactobacillus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000008151 electrolyte solution Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000012792 lyophilization process Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000002525 ultrasonication Methods 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 150000002168 ethanoic acid esters Chemical class 0.000 description 2
- 235000021022 fresh fruits Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000021579 juice concentrates Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- XOTREVBPKJHQEX-UHFFFAOYSA-M sodium;2-(3,3,6,6-tetramethyl-1,8-dioxo-9-phenyl-4,5,7,9-tetrahydro-2h-acridin-10-yl)acetate Chemical compound [Na+].C1C(C)(C)CC(=O)C2=C1N(CC([O-])=O)C(CC(C)(C)CC1=O)=C1C2C1=CC=CC=C1 XOTREVBPKJHQEX-UHFFFAOYSA-M 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000131482 Bifidobacterium sp. Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000178948 Lactococcus sp. Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194022 Streptococcus sp. Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
- A23L3/44—Freeze-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
- A23L5/32—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation using phonon wave energy, e.g. sound or ultrasonic waves
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/20—Ingredients acting on or related to the structure
- A23V2200/22—Coating agent
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/48—Ultrasonic treatment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 초음파를 이용한 프로바이오틱스의 안정성과 코팅효율을 증가시키는 방법 및 그 방법으로 제조된 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 식품조성물에 관한 것으로서, 프로바이오틱스의 배양 및 동결건조 과정에서 초음파를 일정 시간 및 파장으로 처리함으로써 프로바이오틱스의 안정성과 코팅효율을 증가시키는 방법 및 그 방법으로 제조된 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 식품조성물에 관한 것이다.The present invention relates to a method for increasing the stability and coating efficiency of probiotics using ultrasonic waves and a food composition containing the freeze-dried powder of probiotics prepared by the method as an active ingredient. In the process of culturing and freeze-drying the probiotics, And a method of increasing the stability of the probiotics and the coating efficiency by treating the freeze-dried powder with a wavelength, and a food composition containing the freeze-dried powder of probiotics prepared by the method as an active ingredient.
프로바이오틱스(Probiotics)는 '장내 균총을 개선시켜 줌으로써 숙주동물에게 유익한 영향을 주는 생균제제'라고 Fuller가 1989년 정의한 것으로 시작으로 2001년에 발표된 '충분한 양을 섭취하였을 때 숙주의 건강에 도움이 되는 살아있는 미생물'이라는 FAO/WHO 정의가 널리 사용되고 있다. 이에 더하여 1999년 Salminen 등은 '숙주에 유익한 작용을 갖는 미생물 제제 또는 미생물의 성분'으로 정의하여 생균에서 사균으로까지 프로바이오틱스의 범위를 확대시킨 해석도 있다. 프로바이오틱스를 포함한 인간의 장내 미생물이 인간의 건강에 중요한 영향을 미친다는 연구결과 및 과학적 자료가 증가함에 따라 프로바이오틱스에 대한 소비자들의 인식이 더욱 확대되었으며, 그에 따라 프로바이오틱스 제품의 수요가 점차 증가하고 있다. 현재 식약처에서 등재한 락토바실러스(Lactobacillus) 11종(L. acidophilus, L. casei, L. gasseri, L. delbruekii subsp. bulgaricus, L. helveticus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius)과 락토코커스(Lactococcus) 1종(Lc. lactis), 엔테로코커스(Enterococcus) 2종(E. faecium, E. faecalis), 스트렙토코커스(Streptococcus) 1종(S. thermophilus), 비피도박테리움(Bifidobacterium) 4종(B. bifidum, B. breve, B. longum, B. animalis subsp. lactis)까지 19종의 균주에 대하여 프로바이오틱스로 고시하였고 많은 기업체들이 프로바이오틱스에 연구 및 제품을 판매하고 있다.Probiotics is a probiotic agent that improves intestinal microflora and thus has a beneficial effect on host animals. Fuller defines it in 1989 and has published in 2001 the 'Probiotics' FAO / WHO definition of 'living microorganisms' is widely used. In addition, Salminen et al. In 1999 defined "microbial agents or components of microorganisms that have beneficial effects on the host" and have extended the range of probiotics from live cells to dead cells. As research findings and scientific data suggest that human intestinal microorganisms, including probiotics, have a significant impact on human health, consumers are increasingly aware of probiotics and the demand for probiotic products is increasing. Lactobacillus 11 species ( L. acidophilus, L. casei, L. gasseri, L. delbruekii subsp. Bulgaricus, L. helveticus, L. fermentum, L. paracasei, L. plantarum, L Lactobacillus reuteri, L. rhamnosus and L. salivarius ), Lactococcus 1 ( Lc. lactis ), Enterococcus 2 ( E. faecium, E. faecalis ), Streptococcus 1 the S. thermophilus), Bifidobacterium (Bifidobacterium) 4 jong (B. bifidum, B. breve, B. longum, B. animalis subsp. was announced as probiotics with respect to the 19 kinds of strains to lactis) many companies are probiotics Research and sell products.
대표적인 프로바이오틱스의 기능성으로는 유해균 억제, 유익균 증식, 배변활동에 원활하게 도움을 주는 기능성 이외에 수많은 연구와 임상결과에 따르면 정장작용, 과민성장증후군, 아토피, 변비, 여성 질환 등 다양한 효능을 가지고 있다. 하지만 이러한 프로바이오틱스도 균주 자체가 단백질로 구성이 되어있기 때문에 체내로 투입시 위산 및 담즙산에 의해 세포막이 손상이 되면서 프로바이오틱스의 본래의 기능성을 나타내지 못하고 있다. 따라서 이러한 문제점을 극복하고자 현재 프로바이오틱스를 생산하는 업계에서는 고농도의 균주를 투입하거나 혹은 추가적인 공정을 통해서 코팅을 하여 제품을 판매하고 있는데, 특히 고농도의 균주의 투입에 의한 코팅 기술은 제품의 가격이 상승하면서 소비자에게 큰 부담을 줄 수 있을 뿐만 아니라 일일 섭취량의 이상의 생균을 섭취하게 되면 부작용이 일어날 수 있는 문제점이 있다. The functionalities of representative probiotics include various functions such as suppression of harmful bacteria, proliferation of beneficial bacteria, improvement of function of bowel movement, and various other researches and clinical results. However, these probiotics are also composed of proteins because the strains themselves contain proteins, and when they are put into the body, the membranes are damaged by stomach acid and bile acid, and thus they do not show the original functionality of probiotics. Therefore, in order to overcome these problems, in the industry producing probiotics, a high concentration of strains is added or the product is coated by an additional process. In particular, the coating technique by the injection of a high concentration of the strain increases the price of the product It is not only a great burden to consumers but also a problem that side effects can occur if more than one daily intake of live cells is consumed.
또한, 추가적인 공정에 의한 코팅 기술은 고가의 설비와 코팅제로 인하여 제품의 단가 상승이 일어나고, 추가적인 공정이 추가됨에 따라 프로바이오틱스의 안정성을 확보하기 힘든 단점도 있다.In addition, the additional coating process has the disadvantage that it is difficult to secure the stability of the probiotics as the cost of the product increases due to expensive facilities and coatings, and additional processes are added.
한편, 대한민국 등록특허공보 제10-1605516호(2016.03.23)에는 유산균의 배양 중 또는 유산균을 배양한 후 프롤린을 첨가하여 유산균의 동결건조 후 생존율, 저장안정성, 내산성 및 내담즙성을 증가시키는 방법이 개시되어 있으나 원가를 상승시키거나 맛에 영향을 주는 문제점이 존재한다.On the other hand, Korean Patent Registration No. 10-1605516 (Mar. 23, 2016) discloses a method of increasing the survival rate, storage stability, acid resistance and biliary cholesterol after lyophilization of lactic acid bacteria by adding proline during culturing of lactic acid bacteria or culturing of lactic acid bacteria There is a problem that the cost is increased or the taste is affected.
이에 본 발명자들은 프로바이오틱스의 배양 및 동결건조 과정에서 프로바이오틱스가 사멸하지 않을 정도의 초음파를 통한 스트레스를 주면 프로바이오틱스의 생존율 및 안정성이 높아지고, 코팅제가 골고루 분산되어 코팅효율이 높아져 프로바이오틱스의 유통안정성이 개선됨을 확인하여 본 발명을 완성하게 되었다.Accordingly, the inventors of the present invention found that when ultrasound-induced stress is applied to the probiotics in the course of culturing and freeze-drying the probiotics, survival rate and stability of the probiotics are enhanced, coating agents are uniformly dispersed, coating efficiency is improved, and distribution stability of probiotics is improved Thereby completing the present invention.
본 발명의 목적은 프로바이오틱스의 배양 및 동결건조 과정에서 초음파를 처리함으로써 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법을 제공하는 것이다.It is an object of the present invention to provide a method for increasing the stability and coating efficiency of probiotics by treating ultrasound during cultivation and lyophilization of probiotics.
본 발명의 다른 목적은 프로바이오틱스의 배양 및 동결건조 과정에서 초음파를 처리함으로써 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법을 통하여 제조된 프로바이오틱스의 동결건조분말을 유효성분으로 함유하는 발효유, 건강기능식품, 기능성 음료 등 식품조성물을 제공하는 것이다.Another object of the present invention is to provide a fermented milk containing a lyophilized powder of probiotics prepared by a method of increasing the stability and coating efficiency of probiotics by treating ultrasonic waves during cultivation and lyophilization of probiotics, And to provide a food composition such as a beverage.
상기의 목적을 달성하기 위하여, 본 발명은 (a)프로바이오틱스 배양액에 초음파를 처리하는 단계; (b)상기 (a)단계의 초음파 처리된 프로바이오틱스 배양액을 농축하여 프로바이오틱스 농축액을 제조하는 단계; (c)상기 (b)단계의 프로바이오틱스 농축액에 코팅제를 첨가하는 단계; 및 (d)상기 (c)단계의 프로바이오틱스 농축액을 동결건조하는 단계를 포함하는 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법(도 1 참조)과 그 방법으로 제조된 프로바이오틱스의 동결건조분말을 유효성분으로 함유하는 발효유, 건강기능식품, 기능성 음료 등 식품조성물을 제공하는 것을 특징으로 한다.In order to accomplish the above object, the present invention provides a method for culturing a probiotic culture, comprising the steps of: (a) (b) concentrating the ultrasound-treated probiotic culture solution of step (a) to prepare a probiotic concentrate; (c) adding a coating agent to the probiotic concentrate of step (b); And (d) lyophilizing the probiotic concentrate obtained in the step (c). The lyophilized powder of probiotics prepared by the method and the method for enhancing the stability of the probiotics and the coating efficiency A health functional food, a functional beverage, and the like.
또한, 본 발명은 (a)프로바이오틱스 배양액을 농축하여 프로바이오틱스 농축액을 제조하는 단계; (b)상기 (a)단계의 프로바이오틱스 농축액에 코팅제를 첨가하면서 초음파를 처리하는 단계; 및 (c)상기 (b)단계의 초음파 처리된 프로바이오틱스 농축액을 동결건조하는 단계를 포함하는 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법(도 2 참조)과 그 방법으로 제조된 프로바이오틱스의 동결건조분말을 유효성분으로 함유하는 발효유, 건강기능식품, 기능성 음료 등 식품조성물을 제공하는 것을 특징으로 한다.The present invention also provides a method for producing a probiotic concentrate, comprising the steps of: (a) preparing a probiotic concentrate by concentrating the probiotic culture; (b) treating ultrasound while adding a coating agent to the probiotic concentrate of step (a); And (c) lyophilizing the ultrasound-treated probiotic concentrate of step (b) (see FIG. 2) and a lyophilized powder of probiotics prepared by the method The present invention provides a food composition comprising fermented milk, health functional food, functional beverage and the like as an effective ingredient.
또한, 본 발명은 (a)프로바이오틱스 배양액에 초음파를 처리하는 단계; (b)상기 (a)단계의 초음파 처리된 프로바이오틱스 배양액을 농축하여 프로바이오틱스 농축액을 제조하는 단계; (c)상기 (b)단계의 프로바이오틱스 농축액에 코팅제를 첨가하면서 초음파를 처리하는 단계; 및 (d)상기 (c)단계의 초음파 처리된 프로바이오틱스 농축액을 동결건조하는 단계를 포함하는 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법(도 3 참조)과 그 방법으로 제조된 프로바이오틱스의 동결건조분말을 유효성분으로 함유하는 발효유, 건강기능식품, 기능성 음료 등 식품조성물을 제공하는 것을 특징으로 한다.The present invention also provides a method for producing a probiotic culture, comprising the steps of: (a) (b) concentrating the ultrasound-treated probiotic culture solution of step (a) to prepare a probiotic concentrate; (c) treating ultrasound while adding a coating agent to the probiotic concentrate of step (b); And (d) lyophilizing the ultrasound-treated probiotic concentrate obtained in step (c) (see FIG. 3) and a lyophilized powder of probiotics prepared by the method. The present invention provides a food composition comprising fermented milk, health functional food, functional beverage and the like as an effective ingredient.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에 따른 프로바이오틱스(Probiotics)는 락토바실러스 속(Lactobacillus sp.), 비피도박테리움 속(Bifidobacterium sp.), 스트렙토코커스 속(Streptococcus sp.), 락토코커스 속(Lactococcus sp.) 유산균으로서, 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 가세리(Lactobacillus gasseri), 락토바실러스 델부르키 에스에스피 불가리쿠스actobacillus delbrueckii ssp. bulgaricus), 락토바실러스 헬베티쿠스(Lactobacillus helveticus), 락토바실러스 퍼멘텀(Lactobacillus fermentum), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 루테리(Lactobacillus reuteri), 락토코커스 락티스(Lactococcus lactis), 스트렙토코커스 써모필러스(Streptococcus thermophilus), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 비피덤(Bifidobacterium bifidum), 비피도박테리움 브레베(Bifidobacterium breve), 비피도박테리움 에니멀리스 에스에스피 락티스(Bifidobacterium animalis ssp. lactis) 균주 등이 해당된다.Probiotics according to the present invention are useful as Lactobacillus sp., Bifidobacterium sp., Streptococcus sp., Lactococcus sp. Lactic acid bacteria, Lactobacillus sp. Lactobacillus plantarum , Lactobacillus acidophilus , Lactobacillus casei , Lactobacillus gasseri , Lactobacillus delbrueckii ssp, Lactobacillus delbrueckii ssp, Lactobacillus sp. . bulgaricus), Lactobacillus helveticus (Lactobacillus helveticus), Lactobacillus buffer momentum (Lactobacillus fermentum), Lactobacillus para casei (Lactobacillus paracasei), Lactobacillus ramno suspension (Lactobacillus rhamnosus), Lactobacillus ruteri (Lactobacillus reuteri), Lactobacillus Lactococcus lactis , Streptococcus thermophilus , Bifidobacterium longum , Bifidobacterium bifidum , Bifidobacterium breve , Bifidobacterium spp ., Bifidobacterium spp ., Bifidobacterium spp . And Bifidobacterium animalis ssp. Lactis strains.
본 발명에 따른 상기 프로바이오틱스의 배양은 MRS broth 배지 등 종래의 공지된 통상적인 유산균 배양배지 및 배양조건에서 실시한다.The cultivation of the probiotics according to the present invention is carried out under conventionally known conventional lactic acid bacteria culture medium and culture conditions such as MRS broth medium.
본 발명에 따른 프로바이오틱스 배양액을 농축하여 프로바이오틱스 농축액을 제조하는 방법은 종래의 공지된 통상적인 원심분리 방법을 이용한다.The conventionally known conventional centrifugation method is used as a method for preparing the probiotic concentrate by concentrating the probiotic culture solution according to the present invention.
본 발명에 따른 프로바이오틱스 농축액을 동결건조하는 방법은 종래의 공지된 통상적인 동결건조 방법을 이용한다.The method of lyophilizing the probiotic concentrate according to the present invention uses a conventionally known conventional freeze-drying method.
본 발명에 따른 코팅제는 키토산(chitosan), 말토덱스트린(malto-dextrin), 난소화성 덱스트린(indigestible dextrin), 잔탄검(xanthan gum, XG), 구아검(guar gum, GG), 카르복시메틸셀룰로오스(carboxymethyl cellulose, CMC), 하이드록시에틸셀룰로오스(hydroxyethylcellulose, HEC), 폴리비닐피롤리돈(polyvinylpyrroridone, PVP), 카보폴(carbopol), 소듐알기네이트(sodium alginate), 프로필렌글리콜 알기네이트(propylene glycol alginate), 알지네이트(alginate), 폴리에틸렌글리콜(polyethyleneglycol, PEG), 트리아세틴(triacetin), 프로필렌 글리콜(propylene glycol), 아세틸트리에틸 시트레이트(acetyl triethyl citrate) 또는 트리에틸 시트레이트(triethyl citrate)가 사용될 수 있고, 동결보호제는 탈지분유, 프락토올리고당, 트리할로오스(trehalose), 말토덱스트린(maltodextrin) 또는 글리세린(glycerin)이 사용될 수 있다. The coating agent according to the present invention can be used in combination with chitosan, malto-dextrin, indigestible dextrin, xanthan gum, XG, guar gum, carboxymethylcellulose, cellulose, CMC), hydroxyethylcellulose (HEC), polyvinylpyrrolidone (PVP), carbopol, sodium alginate, propylene glycol alginate, Alginate, polyethyleneglycol (PEG), triacetin, propylene glycol, acetyl triethyl citrate or triethyl citrate may be used, The cryoprotectant may be skimmed milk powder, fructooligosaccharide, trehalose, maltodextrin or glycerin.
본 발명에 따른 초음파 처리는 프로바이오틱스(Probiotics)가 사멸되지 않을 정도의 환경스트레스(environment stress)를 가하기 위하여 각각 100Hz, 200Hz, 300Hz,, 600Hz, 1000Hz 초음파 파장을 각각 1분, 2분, 5분, 7분, 10분 동안 처리 한다.The ultrasound treatment according to the present invention was performed by applying ultrasound waves of 100 Hz, 200 Hz, 300 Hz, 600 Hz, and 1000 Hz respectively for 1 minute, 2 minutes, 5 minutes, and 1 hour, respectively, in order to apply environmental stress to the extent that the probiotics are not killed. 7 minutes, 10 minutes.
이때, 프로바이오틱스가 사멸하지 않을 정도의 초음파를 통한 스트레스를 주어 프로바이오틱스의 생존율 및 안정성을 높이고, 코팅제가 골고루 분산되어 코팅효율을 높여 프로바이오틱스의 유통안정성을 개선시키고자 초음파 처리는 ⅰ)프로바이오틱스 배양액, ⅱ)프로바이오틱스 농축액에 코팅제를 첨가하는 과정, ⅲ)프로바이오틱스 배양액 및 프로바이오틱스 농축액에 코팅제를 첨가하는 과정 모두에 할 수 있다.In order to improve the survival rate and stability of probiotics by providing ultrasonic stress to the extent that the probiotics do not kill, and to improve the distribution stability of the probiotics by increasing the coating efficiency by dispersing the coating agent evenly, the ultrasonic treatment is performed by: i) Adding the coating agent to the probiotic concentrate, and iii) adding the coating agent to the probiotic culture solution and the probiotic concentrate.
또한, 본 발명에 따른 프로바이오틱스의 배양 및 동결건조 과정에서 초음파를 처리함으로써 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법을 통하여 제조된 프로바이오틱스의 동결건조분말을 유효성분으로 함유하는 식품조성물은 식품, 식품첨가제, 음료, 음료첨가제, 발효유, 건강기능식품 등으로 사용될 수 있다. 식품, 식품첨가제, 음료, 음료첨가제, 또는 건강기능식품으로 사용되는 경우, 각종 식품류, 발효유, 육류, 음료수, 초콜렛, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 알코올 음료, 비타민 복합제, 주류 및 그 밖의 건강기능식품일 수 있으나, 이에 한정되는 것은 아니다.Also, the food composition containing the lyophilized powder of probiotics prepared by the method of increasing the stability and coating efficiency of the probiotics by treating the ultrasonic wave in the culturing and lyophilizing process of the probiotics according to the present invention, , Drinks, beverage additives, fermented milk, health functional foods, and the like. When used as a food, a food additive, a beverage, a beverage additive, or a health functional food, it is possible to use various foods, fermented milk, meat, beverage, chocolate, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, But may be, but not limited to, a combination, a mainstream and other health functional food.
특히, 본 발명에 따른 프로바이오틱스의 배양 및 동결건조 과정에서 초음파를 처리함으로써 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법을 통하여 제조된 프로바이오틱스의 동결건조분말을 유효성분으로 함유하는 발효유는 프로바이오틱스의 동결건조분말, 유산균 배양액 및 혼합과즙시럽을 일정비율로 조합하여 150bar에서 균질한 후 10℃ 이하로 냉각한 후 용기에 포장하여 발효유를 제조한다.In particular, the fermented milk containing the lyophilized powder of probiotics prepared by the method of increasing the stability and coating efficiency of the probiotics by processing the ultrasound in the culturing and lyophilizing process of the probiotics according to the present invention is characterized in that the lyophilized powder of probiotics , Lactic acid bacteria culture solution and mixed juice syrup are mixed at a certain ratio, homogenized at 150 bar, cooled to below 10 ° C, and packaged in a container to prepare fermented milk.
또한, 본 발명에 따른 프로바이오틱스의 배양 및 동결건조 과정에서 초음파를 처리함으로써 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법을 통하여 제조된 프로바이오틱스의 동결건조분말을 유효성분으로 함유하는 기능성 음료는 혼합과즙시럽, 프로바이오틱스의 동결건조분말 및 물을 일정한 비율로 조합하여 150bar에서 균질한 후 10℃ 이하로 냉각한 후 유리병, 패트병 등 소포장 용기에 포장하여 기능성 음료를 제조한다.The functional beverage containing the lyophilized powder of probiotics prepared by the method of increasing the stability of the probiotics and the coating efficiency by treating the ultrasound in the culturing and lyophilizing process of the probiotics according to the present invention can be used as a mixed nutritional syrup, The lyophilized powder of probiotics and water are mixed at a constant ratio, homogenized at 150 bar, cooled to below 10 ° C, and packaged in small containers such as glass bottles and plastic bottles to produce functional beverages.
또한, 본 발명에 따른 프로바이오틱스의 배양 및 동결건조 과정에서 초음파를 처리함으로써 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법을 통하여 제조된 프로바이오틱스의 동결건조분말을 유효성분으로 함유하는 건강기능식품은 프로바이오틱스의 동결건조분말을 포함하는 것 이외에 영양보조 성분으로 비타민 B1, B2, B5, B6, E 및 초산에스테르, 니코틴산 아미드, 올리고당 등이 첨가될 수 있으며 여타의 식품 첨가물이 첨가되어도 무방하다.In addition, the health functional food containing the lyophilized powder of probiotics prepared by the method of increasing the stability and coating efficiency of the probiotics by processing the ultrasonic wave in the culturing and lyophilizing process of the probiotics according to the present invention, In addition to containing dry powder, vitamin B 1 , B 2 , B 5 , B 6 , E and acetic acid ester, nicotinic amide, oligosaccharide, etc. may be added as nutritional supplement components and other food additives may be added.
본 발명은 프로바이오틱스의 배양 및 동결건조 과정에서 ⅰ)프로바이오틱스 배양액, ⅱ)프로바이오틱스 농축액에 코팅제를 첨가하는 과정, ⅲ)프로바이오틱스 배양액 및 프로바이오틱스 농축액에 코팅제를 첨가하는 과정 모두에 초음파를 처리하여 프로바이오틱스의 안정성 및 코팅효율을 높임으로써 동결건조 단계 및 동결건조 후 프로바이오틱스 동결건조분말의 저온 또는 고온에서의 생존율을 향상시키고, 소화관 생존율이 높아 인체 내 장도달률을 높여주는 프로바이오틱스 동결건조 분말을 유효성분으로 함유하는 발효유, 건강기능식품, 기능성 음료 등 식품조성물로 사용될 수 있다.The present invention relates to a method for culturing and freeze-drying a probiotic, comprising the steps of: i) adding a coating agent to a probiotic culture solution, ii) adding a coating agent to the probiotic concentrate, and iii) adding a coating agent to the probiotic culture solution and the probiotic concentrate, Dried fruit of the probiotic lyophilized powder as an active ingredient by increasing the coating efficiency, improving the survival rate at low or high temperature of the lyophilized powder of probiotics after freeze-drying and freeze-drying, and increasing the survival rate of the digestive tract, Health functional foods, and functional beverages.
도 1은 본 발명의 프로바이오틱스 배양액에 초음파 처리를 하는 프로바이오틱스의 동결건조 과정을 나타낸 모식도이다.
도 2는 본 발명의 프로바이오틱스 농축액에 코팅제를 첨가하는 과정에 초음파 처리를 하는 프로바이오틱스의 동결건조 과정을 나타낸 모식도이다.
도 3은 본 발명의 프로바이오틱스 배양액 및 프로바이오틱스 농축액에 코팅제를 첨가하는 과정 모두에 초음파 처리를 하는 프로바이오틱스의 동결건조 과정을 나타낸 모식도이다.1 is a schematic view showing a lyophilization process of a probiotic to be subjected to ultrasonic treatment in the culture medium of probiotics of the present invention.
2 is a schematic view showing a lyophilization process of a probiotic to be subjected to ultrasonic treatment in the process of adding a coating agent to the probiotic concentrate of the present invention.
FIG. 3 is a schematic view showing a lyophilization process of a probiotic to be subjected to ultrasonic treatment in a process of adding a coating agent to the probiotic culture solution and the probiotic concentrate of the present invention.
이하, 실시예를 통하여 본 발명을 보다 상세하게 설명한다. 그러나, 다음의 실시예는 본 발명의 범위를 한정하는 것은 아니며, 본 발명의 기술적 사상의 범위 내에서 당업자에 의한 통상적인 변화가 가능하다.Hereinafter, the present invention will be described in more detail with reference to Examples. However, the following embodiments are not intended to limit the scope of the present invention, and ordinary variations by those skilled in the art are possible within the scope of the technical idea of the present invention.
<실시예 1>≪ Example 1 >
1-1. 배양 후 초음파 처리된 락토바실러스 플란타룸( Lactobacillus plantarum ) HY7715 동결건조분말 제조 1-1. After cultivation, lyophilized Lactobacillus plantarum HY7715 lyophilized powder was prepared.
락토바실러스 플란타룸(Lactobacillus plantarum) HY7715을 MRS broth 배지에서 배양한 후, 1차 환경스트레스(environment stress)를 가하기 위하여 각각 1분, 2분, 5분, 7분, 10분 동안 100Hz의 일정한 파장으로 초음파 처리를 하였다. 초음파 처리가 완료된 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715 배양액을 8,000rpm에서 15분 동안 원심분리를 하여 얻은 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715 농축액에 대하여 코팅제 및 동결보호제로써 가압 살균된 10중량%의 탈지분유가 함유된 수용액을 1:1의 중량비로 혼합한 다음, 영하 70℃에서 6시간 동안 동결 후 동결건조분말을 제조하였다. Lactobacillus plantarum HY7715 was cultivated in an MRS broth medium and subjected to a constant wavelength of 100 Hz for 1 minute, 2 minutes, 5 minutes, 7 minutes, and 10 minutes, respectively, in order to apply primary environmental stress Was subjected to ultrasonic treatment. The Lactobacillus plantarum HY7715 culture supernatant was subjected to centrifugation at 8,000 rpm for 15 minutes. The Lactobacillus plantarum HY7715 concentrate was coated with 10 g of pressure-sterilized % Of skimmed milk powder was mixed at a weight ratio of 1: 1, and then freeze-dried powder was prepared by freezing at -70 ° C for 6 hours.
1-2. 배양 후 초음파 처리된 비피도박테리움 롱검( Bifidobacterium longum ) HY8001 동결건조분말 제조 1-2. Preparation of freeze-dried powder of Bifidobacterium longum HY8001 ultrasonicated after incubation
상기 실시예 1-1의 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715 대신에 비피도박테리움 롱검(Bifidobacterium longum) HY8001을 사용한 것을 제외하고는 상기 실시예 1-1과 동일한 방법으로 제조하였다.Except that Bifidobacterium longum HY8001 was used in place of Lactobacillus plantarum HY7715 of Example 1-1.
1-3. 배양 후 초음파 처리된 고시형 프로바이오틱스 동결건조분말 제조 1-3. Manufacture of freeze-dried powder of high-quality probiotic after ultrasonication after culturing
하기의 표 1의 각각의 프로바이오틱스를 MRS broth 배지에서 배양한 후, 1차 환경스트레스(environment stress)를 가하기 위하여 5분 동안 100Hz의 일정한 파장으로 초음파 처리를 하였다. 초음파 처리가 완료된 각각의 프로바이오틱스 배양액을 8,000rpm에서 15분 동안 원심분리를 하여 얻은 각각의 프로바이오틱스 농축액에 대하여 코팅제 및 동결보호제로써 가압 살균된 10중량%의 탈지분유가 함유된 수용액을 1:1의 중량비로 혼합한 다음, 영하 70℃에서 6시간 동안 동결 후 동결건조분말을 제조하였다.Each of the probiotics of Table 1 below was cultured in an MRS broth medium and subjected to ultrasonic treatment at a constant wavelength of 100 Hz for 5 minutes in order to apply primary environmental stress. Each of the probiotic cultures, which had been subjected to the ultrasonication treatment, were centrifuged at 8,000 rpm for 15 minutes, and each of the obtained probiotic concentrates was coated with an aqueous solution containing pressurized sterilized 10% by weight of skimmed milk powder as a coating agent and a cryoprotectant at a weight ratio of 1: , And then freeze-dried powder was prepared by freezing at -70 ° C for 6 hours.
<실시예 2>≪ Example 2 >
2-1. 코팅 후 초음파 처리된 락토바실러스 플란타룸( Lactobacillus plantarum ) HY7715 동결건조분말 제조 2-1. Preparation of lyophilized Lactobacillus plantarum HY7715 lyophilized powder after coating
락토바실러스 플란타룸(Lactobacillus plantarum) HY7715을 MRS broth 배지에서 배양한 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715 배양액을 8,000rpm에서 15분 동안 원심분리를 하여 얻은 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715 농축액에 대하여 코팅제 및 동결보호제로써 가압 살균된 10중량%의 탈지분유가 함유된 수용액을 1:1의 중량비로 혼합하는 동안 1차 환경스트레스(environment stress)를 가하기 위하여 각각 1분, 2분, 5분, 7분, 10분 동안 100Hz의 일정한 파장으로 초음파 처리를 하였다. 그런 다음, 영하 70℃에서 6시간 동안 동결 후 동결건조분말을 제조하였다.Lactobacillus Planta room (Lactobacillus plantarum) a Lactobacillus Planta room (Lactobacillus plantarum) Lactobacillus Planta room (Lactobacillus plantarum) obtained by centrifugation for 15 minutes at 8,000rpm HY7715 culture solution cultured in MRS broth medium HY7715 HY7715 For the concentrate, 1: 1, 2: 5, 5: 1, 1, 2, 3, 4 and 5 minutes were added to the concentrate in order to apply primary stress to the environment while mixing the coating solution and the aqueous solution containing pressurized sterilized 10% Min, 7 min, and 10 min with a constant wavelength of 100 Hz. Then, a lyophilized powder was prepared after freezing at minus 70 ° C for 6 hours.
2-2. 코팅 후 초음파 처리된 비피도박테리움 롱검( Bifidobacterium longum ) HY8001 동결건조분말 제조 2-2. Preparation of freeze-dried powder of Bifidobacterium longum HY8001 ultrasonically treated after coating
상기 실시예 2-1의 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715 대신에 비피도박테리움 롱검(Bifidobacterium longum) HY8001을 사용한 것을 제외하고는 상기 실시예 2-1과 동일한 방법으로 제조하였다.The procedure of Example 2-1 was repeated except that Bifidobacterium longum HY8001 was used instead of Lactobacillus plantarum HY7715 of Example 2-1.
2-3. 코팅 후 초음파 처리된 고시형 프로바이오틱스 동결건조분말 제조 2-3. Manufacture of lyophilized freeze-dried powder with ultrasonic treatment after coating
하기의 표 1의 각각의 프로바이오틱스를 MRS broth 배지에서 배양한 각각의 프로바이오틱스 배양액을 8,000rpm에서 15분 동안 원심분리를 하여 얻은 각각의 프로바이오틱스 농축액에 대하여 코팅제 및 동결보호제로써 가압 살균된 10중량%의 탈지분유가 함유된 수용액을 1:1의 중량비로 혼합하는 동안 1차 환경스트레스(environment stress)를 가하기 위하여 5분 동안 100Hz의 일정한 파장으로 초음파 처리를 하였다. 그런 다음, 영하 70℃에서 6시간 동안 동결 후 동결건조분말을 제조하였다.Each of the probiotics cultured in the MRS broth medium of each of the following probiotics shown in the following Table 1 was centrifuged at 8,000 rpm for 15 minutes, and each of the obtained probiotic concentrates was coated with 10% by weight of pressurized sterilized Ultrasonic treatment was performed at a constant wavelength of 100 Hz for 5 minutes in order to apply primary environmental stress while mixing the aqueous solution containing powdered milk at a weight ratio of 1: 1. Then, a lyophilized powder was prepared after freezing at minus 70 ° C for 6 hours.
<실시예 3>≪ Example 3 >
3-1. 초음파가 복합 처리된 락토바실러스 플란타룸( Lactobacillus plantarum ) HY7715 동결건조분말 제조 3-1. Preparation of freeze-dried powder of Lactobacillus plantarum HY7715 complexed with ultrasound
락토바실러스 플란타룸(Lactobacillus plantarum) HY7715을 MRS broth 배지에서 배양한 후, 1차 환경스트레스(environment stress)를 가하기 위하여 각각 1분, 2분, 5분, 7분, 10분 동안 100Hz의 일정한 파장으로 초음파 처리를 하였다. 초음파 처리가 완료된 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715 배양액을 8,000rpm에서 15분 동안 원심분리를 하여 얻은 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715 농축액에 대하여 코팅제 및 동결보호제로써 가압 살균된 10중량%의 탈지분유가 함유된 수용액을 1:1의 중량비로 혼합하는 동안 2차 환경스트레스(environment stress)를 가하기 위하여 각각 1분, 2분, 5분, 7분, 10분 동안 100Hz의 일정한 파장으로 초음파 처리를 하였다. 그런 다음, 영하 70℃에서 6시간 동안 동결 후 동결건조분말을 제조하였다. Lactobacillus plantarum HY7715 was cultivated in an MRS broth medium and subjected to a constant wavelength of 100 Hz for 1 minute, 2 minutes, 5 minutes, 7 minutes, and 10 minutes, respectively, in order to apply primary environmental stress Was subjected to ultrasonic treatment. The Lactobacillus plantarum HY7715 culture supernatant was subjected to centrifugation at 8,000 rpm for 15 minutes. The Lactobacillus plantarum HY7715 concentrate was coated with 10 g of pressure-sterilized % Of an aqueous solution containing skimmed milk powder at a weight ratio of 1: 1 During the mixing, ultrasonic treatment was applied at a constant wavelength of 100 Hz for 1, 2, 5, 7, and 10 minutes to add secondary environmental stresses. Then, a lyophilized powder was prepared after freezing at minus 70 ° C for 6 hours.
3-2. 초음파가 복합 처리된 비피도박테리움 롱검( Bifidobacterium longum ) HY8001 동결건조분말 제조 3-2. Preparation of freeze-dried powder of Bifidobacterium longum HY8001 complex-treated with ultrasound
상기 실시예 3-1의 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715 대신에 비피도박테리움 롱검(Bifidobacterium longum) HY8001을 사용한 것을 제외하고는 상기 실시예 3-1과 동일한 방법으로 제조하였다.Was prepared in the same manner as in Example 3-1 except that Bifidobacterium longum HY8001 was used instead of Lactobacillus plantarum HY7715 of Example 3-1.
3-3. 초음파가 복합 처리된 고시형 프로바이오틱스 동결건조분말 제조 3-3. Manufacture of freeze-dried powder of high-quality probiotics combined with ultrasound
하기의 표 1의 각각의 프로바이오틱스를 MRS broth 배지에서 배양한 후, 각각의 프로바이오틱스 배양액을 1차 환경스트레스(environment stress)를 가하기 위하여 5분 동안 100Hz의 일정한 파장으로 초음파 처리를 하였다. 초음파 처리가 완료된 각각의 프로바이오틱스 배양액을 8,000rpm에서 15분 동안 원심분리를 하여 얻은 각각의 프로바이오틱스 농축액에 대하여 코팅제 및 동결보호제로써 가압 살균된 10중량%의 탈지분유가 함유된 수용액을 1:1의 중량비로 혼합하는 동안 2차 환경스트레스(environment stress)를 가하기 위하여 5분 동안 100Hz의 일정한 파장으로 초음파 처리를 하였다. 그런 다음, 영하 70℃에서 6시간 동안 동결 후 동결건조분말을 제조하였다.Each of the probiotics of the following Table 1 was cultured in an MRS broth medium, and each of the probiotic cultures was subjected to ultrasonic treatment at a constant wavelength of 100 Hz for 5 minutes to apply primary environmental stress. Each of the probiotic cultures, which had been subjected to the ultrasonication treatment, were centrifuged at 8,000 rpm for 15 minutes, and each of the obtained probiotic concentrates was coated with an aqueous solution containing pressurized sterilized 10% by weight of skimmed milk powder as a coating agent and a cryoprotectant at a weight ratio of 1: , Ultrasonic treatment was performed at a constant wavelength of 100 Hz for 5 minutes in order to apply secondary environmental stress during mixing. Then, a lyophilized powder was prepared after freezing at minus 70 ° C for 6 hours.
시험균주
Test strain
<실시예 4><Example 4>
4-1. 배양 후 초음파 처리된 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 발효유의 제조 4-1. Preparation of fermented milk containing the freeze-dried powder of probiotic ultrasonicated after cultivation as an active ingredient
유산균 배양액은 원유 95.36중량%와 탈지분유(또는 혼합분유) 4.6중량%를 교반하여 15℃에서의 비중은 1.0473~1.0475, 적정산도는 0.200~0.220%, pH는 6.55~6.70, 20℃에서의 브릭스(Brix0)는 16.3~16.5% 정도가 되도록 혼합하였다. 혼합 후에 이를 UHT 열처리(135℃에서 2초간 살균)하고 적정온도 냉각한 뒤, 스트렙토코커스 써모필러스균과 유당분해효소(Valley laboratory, USA)를 각기 0.02중량%씩 첨가하고 6시간 동안 배양하여 BCP배지에서의 총 유산균 수가 1.0 X 109cfu/㎖이상, 적정산도가 0.89~0.91%, pH는 4.55~4.65가 되도록 하여 제조하였다. The lactic acid bacteria culture solution was prepared by stirring 95.36% by weight of crude oil and 4.6% by weight of skimmed milk powder (or mixed powdered milk) and having a specific gravity of 1.0473 to 1.0475 at 15 ° C, a titratable acidity of 0.200 to 0.220%, a pH of 6.55 to 6.70, (Brix 0 ) was about 16.3 to 16.5%. After mixing, the mixture was heat-treated with UHT (sterilized at 135 ° C. for 2 seconds) and cooled to an appropriate temperature. Streptococcus thermophilus and lactoseolytic enzyme (Valley laboratory, USA) were added at 0.02 wt% Was 1.0 X 10 9 cfu / ml or more, the titratable acidity was 0.89 to 0.91%, and the pH was 4.55 to 4.65.
혼합과즙시럽은 액상과당 13중량%, 백설탕 5중량%, 혼합과즙농축액 56Brix0 10.9중량%, 펙틴 1.0중량%, 후레쉬후르츠 믹스 에센스 0.1중량% 및 정제수 70중량%를 35℃에서 교반하여 혼합한 후 UHT 열처리(135℃에서 2초간 살균)한 후 냉각하여 제조하였다. The mixed juice syrup was prepared by mixing 13 wt% of liquid fructose, 5 wt% of white sugar, 10.9 wt% of concentrated juice concentrate 56Brix 0 , 1.0 wt% of pectin, 0.1 wt% of fresh fruit mix essence and 70 wt% of purified water, UHT heat treatment (sterilization at 135 캜 for 2 seconds) and cooling.
상기 유산균 배양액 69.5중량%와 상기 실시예 1의 프로바이오틱스 동결건조분말 0.1중량% 및 상기 혼합과즙시럽 30.4중량%를 조합하여 150bar에서 균질한 후 10℃ 이하로 냉각하여 본 발명의 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 발효유를 제조하였다.The 69% by weight of the lactic acid bacteria culture solution was homogenized at 150 bar in combination with 0.1% by weight of the freeze-dried powder of the probiotics of Example 1 and 30.4% by weight of the mixed fruit juice syrup and then cooled to 10 ° C or less to obtain a freeze- To prepare a fermented milk.
4-2. 코팅 후 초음파 처리된 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 발효유의 제조 4-2. Preparation of fermented milk containing the freeze-dried powder of ultrasonic treated probiotics as an active ingredient after coating
상기 실시예 1의 프로바이오틱스 동결건조분말 대신에 상기 실시예 2의 프로바이오틱스 동결건조분말을 사용한 것을 제외하고는 상기 실시예 4-1과 동일한 방법으로 본 발명의 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 발효유를 제조하였다.The lyophilized powder of probiotics of the present invention was used as the active ingredient in the same manner as in Example 4-1 except that the lyophilized powder of probiotics of Example 2 was used instead of the lyophilized powder of probiotic of Example 1, .
4-3. 초음파가 복합 처리된 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 발효유의 제조 4-3. Preparation of fermented milk containing freeze-dried powder of probiotic complex treated with ultrasound as an active ingredient
상기 실시예 1의 프로바이오틱스 동결건조분말 대신에 상기 실시예 3의 프로바이오틱스 동결건조분말을 사용한 것을 제외하고는 상기 실시예 4-1과 동일한 방법으로 본 발명의 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 발효유를 제조하였다.The lyophilized powder of probiotics of the present invention was used as the active ingredient in the same manner as in Example 4-1 except that the lyophilized powder of probiotics of Example 3 was used instead of the lyophilized powder of probiotic of Example 1, .
<실시예 5>≪ Example 5 >
5-1. 배양 후 초음파 처리된 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 기능성 음료의 제조 5-1. Preparation of a functional beverage containing an ultrasound-treated freeze-dried powder of probiotics as an active ingredient after culturing
혼합과즙시럽은 액상과당 13중량%, 백설탕 2.5중량%, 갈색설탕 2.5중량%, 혼합과즙농축액 56Brix0 10.9중량%, 펙틴 1.0중량%, 후레쉬후르츠 믹스 에센스 0.1중량% 및 정제수 70중량%를 35℃에서 교반하여 혼합한 후 UHT열처리(135℃에서 2초간 살균)한 후 냉각하여 제조하였다.Mixing juice syrup was 13% by weight of liquid fructose, white sugar, 2.5% by weight, 2.5% by weight brown sugar, mix juice concentrate 56Brix 0 10.9% by weight of the pectin 1.0% by weight, fresh fruit mix Essence 0.1% by weight and pure water 70 wt% 35 ℃ Followed by UHT heat treatment (sterilization at 135 캜 for 2 seconds), followed by cooling.
그리고, 상기의 방법으로 제조된 혼합과즙시럽 30.4중량%와 상기 실시예 1의 프로바이오틱스 동결건조분말 0.1중량% 및 나머지 정제수 69.5중량% 조합하여 150bar에서 균질한 후 10℃ 이하로 냉각한 후 이를 유리병, 페트병 등 소포장 용기에 포장하여 본 발명의 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 기능성 음료를 제조하였다.Then, 30.4% by weight of the mixed fruit juice syrup prepared by the above method, 0.1% by weight of the lyophilized powder of Example 1, and 69.5% by weight of the remaining purified water were combined and homogenized at 150 bar, , PET bottles, etc., to prepare functional beverages containing the probiotics lyophilized powder of the present invention as an active ingredient.
5-2. 코팅 후 초음파 처리된 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 기능성 음료의 제조 5-2. Preparation of a functional beverage containing the lyophilized powder of ultrasonic treated probiotics as an active ingredient after coating
상기 실시예 1의 프로바이오틱스 동결건조분말 대신에 상기 실시예 2의 프로바이오틱스 동결건조분말을 사용한 것을 제외하고는 상기 실시예 5-1과 동일한 방법으로 본 발명의 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 기능성 음료를 제조하였다.The lyophilized powder of probiotics of the present invention was used as the active ingredient and the lyophilized powder of the probiotics of Example 2 was used in the same manner as in Example 5-1 except that the lyophilized powder of probiotics of Example 2 was used instead of the lyophilized powder of probiotics of Example 1, A beverage was prepared.
5-3. 초음파가 복합 처리된 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 기능성 음료의 제조 5-3. Preparation of a functional beverage containing as an active ingredient a lyophilized powder of probiotics complex-treated with ultrasound
상기 실시예 1의 프로바이오틱스 동결건조분말 대신에 상기 실시예 3의 프로바이오틱스 동결건조분말을 사용한 것을 제외하고는 상기 실시예 5-1과 동일한 방법으로 본 발명의 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 기능성 음료를 제조하였다.The lyophilized powder of probiotics of the present invention was used as the active ingredient in the same manner as in Example 5-1 except that the lyophilized powder of probiotics of Example 3 was used instead of the lyophilized powder of probiotic of Example 1, A beverage was prepared.
<실시예 6>≪ Example 6 >
6-1. 배양 후 초음파 처리된 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 건강기능식품의 제조 6-1. Preparation of Health Functional Foods Containing Ultrasonically Treated Frost-Dried Powder as an Active Ingredient After Cultivation
상기 실시예 1의 프로바이오틱스 동결건조분말 0.1중량%에 영양보조성분(비타민 B1, B2, B5, B6, E 및 초산에스테르, 니코틴산 아미드) 및 올리고당을 상기의 실시예 1의 프로바이오틱스 동결건조분말 100중량부에 대하여 10중량부가 되도록 첨가하여 고속회전 혼합기에서 혼합하였다. 상기 혼합물에 멸균 정제수 10중량부를 첨가, 혼합하고 직경 1~2mm의 과립상으로 성형하였다. 상기 성형된 과립은 50℃의 진공건조기에서 건조시킨 후 12~14메쉬(mesh)를 통과시켜 균일하게 과립을 제조하였다. 상기와 같이 제조된 과립은 적당량씩 압출 성형되어 정제 또는 분말로 되거나 경질캡슐에 충전되어 경질캡슐제품으로 제조하였다.The nutritional supplement components (vitamin B 1 , B 2 , B 5 , B 6 , E and acetic acid ester, nicotinic acid amide) and oligosaccharide were added to 0.1% by weight of the lyophilized powder of the probiotics of Example 1 by lyophilization Was added in an amount of 10 parts by weight based on 100 parts by weight of the powder and mixed in a high-speed rotary mixer. 10 parts by weight of sterilized purified water was added to the mixture, mixed and molded into granules having a diameter of 1 to 2 mm. The molded granules were dried in a vacuum dryer at 50 ° C and then passed through 12 to 14 mesh to uniformly produce granules. The granules thus prepared were extruded in suitable amounts to be purified or powdered or filled into hard capsules to prepare hard capsule products.
6-2. 코팅 후 초음파 처리된 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 건강기능식품의 제조 6-2. Preparation of Health Functional Foods Containing Ultrasonically Treated Frost-Dried Powder as an Active Ingredient After Coating
상기 실시예 1의 프로바이오틱스 동결건조분말 대신에 상기 실시예 2의 프로바이오틱스 동결건조분말을 사용한 것을 제외하고는 상기 실시예 6-1과 동일한 방법으로 본 발명의 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 건강기능식품을 제조하였다.The lyophilized powder of probiotics of the present invention was used as an active ingredient in the same manner as in Example 6-1 except that the lyophilized powder of probiotics of Example 2 was used instead of the lyophilized powder of probiotic of Example 1, Functional foods were prepared.
6-3. 초음파가 복합 처리된 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 건강기능식품의 제조 6-3. Preparation of Health Functional Foods Containing Probiotics Freeze-Dried Powder Combined with Ultrasound as an Active Ingredient
상기 실시예 1의 프로바이오틱스 동결건조분말 대신에 상기 실시예 3의 프로바이오틱스 동결건조분말을 사용한 것을 제외하고는 상기 실시예 6-1과 동일한 방법으로 본 발명의 프로바이오틱스 동결건조분말을 유효성분으로 함유하는 건강기능식품을 제조하였다.The lyophilized powder of probiotics of the present invention was used as an active ingredient in the same manner as in Example 6-1 except that the lyophilized powder of probiotics of Example 3 was used instead of the lyophilized powder of probiotics of Example 1, Functional foods were prepared.
<시험예 1>≪ Test Example 1 >
배양 후 초음파 처리된 프로바이오틱스의 가속 안정성 시험Accelerated stability test of ultrasonic treated probiotics after incubation
장기간 유통시 생균제의 보관 안정성을 기반으로 최적의 초음파 처리 조건을 검토하기 위하여 상기 실시예 1-1 및 실시예 1-2의 프로바이오틱스 동결건조분말 100%중량을 스틱포장하여 온도 40℃, 습도 70%의 조건에서 4주 동안 가속시험을 진행하여 프로바이오틱스의 생존율을 계산하였다.100% weight of the lyophilized powder of probiotics of Examples 1-1 and 1-2 was packed in a stick and kept at a temperature of 40 ° C and a humidity of 70% in order to examine the optimal ultrasonic treatment conditions based on the storage stability of the probiotics during long- The survival rate of probiotics was calculated by accelerated test for 4 weeks.
대조군은 프로바이오틱스 배양 후 초음파 처리가 되지 않은 것을 제외하고는 상기 실시예 1-1 및 실시예 1-2와 동일한 방법으로 제조된 프로바이오틱스 동결건조분말 100중량%를 사용하여 상기와 동일한 방법으로 시험하였다.Control groups were tested in the same manner as above using 100% by weight of lyophilized probiotic powder prepared in the same manner as in Example 1-1 and Example 1-2, except that the ultrasonic treatment was not performed after the cultivation of the probiotics.
상기 '생존율'은 가속안정성시험 진행 후 생존균 수를 가속안정성 시험 진행 전 생존균 수로 나눈 값의 백분율을 의미한다.The 'survival rate' means the percentage of viable cells counted after the accelerated stability test divided by the number of viable cells before the accelerated stability test.
그 결과를 하기의 표 2에 나타내었다.The results are shown in Table 2 below.
하기의 표 2에서 확인할 수 있는 바와 같이, 대조군의 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 생존율은 25.3%, 대조군의 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 생존율은 20.0%인 반면, 실험군은 초음파 처리의 시간과 상관없이 대조군보다 높은 생존율을 보였다. As can be seen in the following Table 2, the survival rate of the control group Lactobacillus plantarum HY7715 was 25.3% and the survival rate of the control group Bifidobacterium longum HY8001 was 20.0% Showed a higher survival rate than the control group regardless of the time of ultrasound treatment.
한편, 가장 높은 생존율을 보인 실험군의 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 생존율은 초음파 처리 5분(생존율: 55.1%), 7분(생존율: 54.1%), 10분(생존율: 54.5%)에서 높은 생존율을 보였고. 5분간 초음파를 처리한 실험군이 가속 조건에서 가장 높은 생존율을 보였다.The survival rate of Lactobacillus plantarum HY7715 in the experimental group with the highest survival rate was 5 minutes (survival rate: 55.1%), 7 minutes (survival rate: 54.1%), 10 minutes (survival rate: 54.5% And high survival rate. Experimental group treated with ultrasound for 5 minutes showed the highest survival rate under accelerated conditions.
또한, 가장 높은 생존율을 보인 실험군의 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 생존율은 초음파 처리 5분(생존율: 47.1%), 7분(생존율: 45.5%), 10분(생존율: 43.5%)에서 높은 생존율을 보였고. 5분간 초음파를 처리한 실험군이 가속 조건에서 가장 높은 생존율을 보였다.The survival rate of Bifidobacterium longum HY8001 in the experimental group with the highest survival rate was 5 minutes (survival rate: 47.1%), 7 minutes (survival rate: 45.5%), 10 minutes (survival rate: 43.5% And high survival rate. Experimental group treated with ultrasound for 5 minutes showed the highest survival rate under accelerated conditions.
<시험예 2>≪ Test Example 2 &
배양 후 초음파 처리된 고시형 프로바이오틱스의 동결건조 생존율 시험Freeze-dried survival rate test of ultrasonicated high-quality probiotics after culture
배양 후 초음파 처리된 프로바이오틱스의 동결과정에서 시험예 1의 가장 높은 생존율을 보인 초음파 처리 조건(5분, 100Hz)에서의 프로바이오틱스의 생존율을 확인하기 위하여 상기 실시예 1의 방법으로 제조된 프로바이오틱스의 동결건조 생존율을 계산하였다.In order to confirm the survival rate of the probiotics under the ultrasound treatment conditions (5 min, 100 Hz) showing the highest survival rate in Test Example 1 during the freezing of the ultrasound-treated probiotics after culturing, the freeze-drying of the probiotics prepared by the method of Example 1 Survival rate was calculated.
상기 '생존율'은 동결건조 후 생존균 수를 동결건조 전 생존균 수로 나눈 값의 백분율을 의미한다.The 'survival rate' means the percentage of viable cells after lyophilization divided by the number of viable cells before lyophilization.
대조군은 프로바이오틱스 배양 후 초음파 처리가 되지 않은 것을 제외하고는 상기 실시예 1과 동일한 방법으로 제조된 프로바이오틱스 동결건조분말을 대상으로 하였다.The control group was a freeze-dried powder of probiotic prepared in the same manner as in Example 1, except that the ultrasonic treatment was not performed after the cultivation of the probiotics.
그 결과를 하기의 표 3에 나타내었다.The results are shown in Table 3 below.
표 3에서 확인할 수 있는 바와 같이, 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 생존율은 대조군의 생존율 보다 약 16% 높았고, 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 생존율은 대조군의 생존율 보다 약 4% 높게 나타났다.As can be seen in Table 3, the survival rate of Lactobacillus plantarum HY7715 was about 16% higher than that of the control group, and the survival rate of Bifidobacterium longum HY8001 was about 4 %.
또한, 기타 고시형 프로바이오틱스(실험군)의 생존율은 최소 9%에서 최대 28%의 사멸률을 보여 최소 22%에서 최대 45%까지의 사멸률을 보인 대조군보다 생존율이 향상됨을 확인하였다.In addition, survival rates of other high-quality probiotics (experimental group) showed a survival rate of at least 9% and up to 28%, and survival rates were improved compared to control groups showing at least 22% and up to 45% survival rate.
<시험예 3>≪ Test Example 3 >
코팅 후 초음파 처리된 프로바이오틱스의 가속 안정성 시험Accelerating stability test of ultrasonic treated probiotics after coating
장기간 유통시 생균제의 보관 안정성을 기반으로 최적의 초음파 처리 조건을 검토하기 위하여 상기 실시예 2-1 및 실시예 2-2의 프로바이오틱스 동결건조분말 100%중량을 스틱포장하여 온도 40℃, 습도 70%의 조건에서 4주 동안 가속시험을 진행하여 프로바이오틱스의 생존율을 계산하였다.100% weight of the lyophilized probiotics of Examples 2-1 and 2-2 was packed in a stick pack, and the temperature was 40 ° C and the humidity was 70%. In order to examine the optimal ultrasonic treatment conditions based on the storage stability of the probiotics during long- The survival rate of probiotics was calculated by accelerated test for 4 weeks.
대조군은 프로바이오틱스 배양 후 초음파 처리가 되지 않은 것을 제외하고는 상기 실시예 2-1 및 실시예 2-2와 동일한 방법으로 제조하여 사용하였다.The control group was prepared and used in the same manner as in Examples 2-1 and 2-2 except that the ultrasonic treatment was not performed after the cultivation of the probiotics.
상기 '생존율'은 가속안정성시험 진행 후 생존균 수를 가속안정성 시험 진행 전 생존균 수로 나눈 값의 백분율을 의미한다.The 'survival rate' means the percentage of viable cells counted after the accelerated stability test divided by the number of viable cells before the accelerated stability test.
그 결과를 하기의 표 4에 나타내었다.The results are shown in Table 4 below.
하기의 표 4에서 확인할 수 있는 바와 같이, 대조군의 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 생존율은 24.1%, 대조군의 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 생존율은 18.9%인 반면, 실험군은 초음파 처리의 시간과 상관없이 대조군보다 높은 생존율을 보였다. As shown in the following Table 4, the survival rate of the control group Lactobacillus plantarum HY7715 was 24.1% and the survival rate of the control group Bifidobacterium longum HY8001 was 18.9% Showed a higher survival rate than the control group regardless of the time of ultrasound treatment.
한편, 가장 높은 생존율을 보인 실험군의 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 생존율은 초음파 처리 5분(생존율: 63.3%), 7분(생존율: 60.2%), 10분(생존율: 60.3%)에서 높은 생존율을 보였고. 5분간 초음파를 처리한 실험군이 가속 조건에서 가장 높은 생존율을 보였다.The survival rate of Lactobacillus plantarum HY7715 in the experimental group with the highest survival rate was 5 minutes (survival rate: 63.3%), 7 minutes (survival rate: 60.2%) and 10 minutes (survival rate: 60.3% And high survival rate. Experimental group treated with ultrasound for 5 minutes showed the highest survival rate under accelerated conditions.
또한, 가장 높은 생존율을 보인 실험군의 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 생존율은 초음파 처리 5분(생존율: 55.3%), 7분(생존율: 52.7%), 10분(생존율: 52.5%)에서 높은 생존율을 보였고. 5분간 초음파를 처리한 실험군이 가속 조건에서 가장 높은 생존율을 보였다.The survival rate of Bifidobacterium longum HY8001 in the experimental group with the highest survival rate was 5 minutes (survival rate: 55.3%), 7 minutes (survival rate: 52.7%) and 10 minutes (survival rate: 52.5% And high survival rate. Experimental group treated with ultrasound for 5 minutes showed the highest survival rate under accelerated conditions.
<시험예 4><Test Example 4>
코팅 후 초음파 처리된 고시형 프로바이오틱스의 동결건조 생존율 시험Freeze-dried survival rate test of ultrasonic treated high quality probiotics after coating
코팅 후 초음파 처리된 프로바이오틱스의 동결과정에서 시험예 3의 가장 높은 생존율을 보인 초음파 처리 조건(5분, 100Hz)에서의 프로바이오틱스의 생존율을 확인하기 위하여 상기 실시예 2의 방법으로 제조된 프로바이오틱스의 동결건조 생존율을 계산하였다.In order to confirm the survival rate of the probiotics under the ultrasound treatment conditions (5 min, 100 Hz) showing the highest survival rate in Test Example 3 in the freezing process of the ultrasound-treated probiotics after coating, the freeze- Survival rate was calculated.
상기 '생존율'은 동결건조 후 생존균 수를 동결건조 전 생존균 수로 나눈 값의 백분율을 의미한다.The 'survival rate' means the percentage of viable cells after lyophilization divided by the number of viable cells before lyophilization.
대조군은 코팅 후 초음파 처리가 되지 않은 것을 제외하고는 상기 실시예 2와 동일한 방법으로 제조된 프로바이오틱스 동결건조분말을 대상으로 하였다.The control group was a freeze-dried powder of probiotic prepared by the same method as in Example 2, except that the coating was not subjected to ultrasonic treatment.
그 결과를 하기의 표 5에 나타내었다.The results are shown in Table 5 below.
표 5에서 확인할 수 있는 바와같이, 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 생존율은 대조군의 생존율 보다 약 23% 높았고, 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 생존율은 대조군의 생존율 보다 약 20% 높았다.As can be seen in Table 5, the survival rate of Lactobacillus plantarum HY7715 was about 23% higher than that of the control group, and the survival rate of Bifidobacterium longum HY8001 was about 20 %.
또한, 기타 고시형 프로바이오틱스(실험군)의 생존율은 최소 2%에서 최대 17%의 사멸률을 보여 최소 21%에서 최대 47%까지의 사멸률을 보인 대조군보다 생존율이 향상됨을 확인하였다.In addition, survival rates of other high-quality probiotics (experimental group) showed a survival rate of at least 2% and up to 17%, indicating that the survival rate was improved compared to the control group showing a survival rate of at least 21% to 47%.
<시험예 5>≪ Test Example 5 >
초음파가 복합 처리된 프로바이오틱스의 가속 안정성 시험Accelerating stability test of ultrasound-combined probiotics
장기간 유통시 생균제의 보관 안정성을 기반으로 최적의 초음파 처리 조건을 검토하기 위하여 상기 실시예 3-1 및 실시예 3-2의 프로바이오틱스 동결건조분말 100%중량을 스틱포장하여 온도 40℃, 습도 70%의 조건에서 4주 동안 가속시험을 진행하여 프로바이오틱스의 생존율을 계산하였다.100% weight of the lyophilized probiotics of Examples 3-1 and 3-2 was packed in a stick and kept at a temperature of 40 ° C and a humidity of 70% in order to examine the optimal ultrasonic treatment conditions based on the storage stability of the probiotics during long- The survival rate of probiotics was calculated by accelerated test for 4 weeks.
대조군은 프로바이오틱스 배양 후 초음파 처리가 되지 않은 것을 제외하고는 상기 실시예 3-1 및 실시예 3-2와 동일한 방법으로 제조하여 사용하였다.The control group was prepared and used in the same manner as in Examples 3-1 and 3-2 except that the ultrasonic treatment was not performed after the cultivation of the probiotics.
상기 '생존율'은 가속안정성시험 진행 후 생존균 수를 가속안정성 시험 진행 전 생존균 수로 나눈 값의 백분율을 의미한다.The 'survival rate' means the percentage of viable cells counted after the accelerated stability test divided by the number of viable cells before the accelerated stability test.
그 결과를 하기의 표 6에 나타내었다.The results are shown in Table 6 below.
하기의 표 6에서 확인할 수 있는 바와 같이, 대조군의 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 생존율은 23.7%, 대조군의 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 생존율은 18.6%인 반면, 실험군은 초음파 처리의 시간과 상관없이 대조군보다 높은 생존율을 보였다. As can be seen in the following Table 6, the survival rate of Lactobacillus plantarum HY7715 in the control group was 23.7% and the survival rate of the control group Bifidobacterium longum HY8001 was 18.6% Showed a higher survival rate than the control group regardless of the time of ultrasound treatment.
한편, 가장 높은 생존율을 보인 실험군의 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 생존율은 초음파 처리 5분(생존율: 60.1%), 7분(생존율: 58.1%), 10분(생존율: 57.3%)에서 높은 생존율을 보였고. 5분간 초음파를 처리한 실험군이 가속 조건에서 가장 높은 생존율을 보였다.The survival rate of Lactobacillus plantarum HY7715 in the experimental group with the highest survival rate was 5 minutes (survival rate: 60.1%), 7 minutes (survival rate: 58.1%), 10 minutes (survival rate: 57.3% And high survival rate. Experimental group treated with ultrasound for 5 minutes showed the highest survival rate under accelerated conditions.
또한, 가장 높은 생존율을 보인 실험군의 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 생존율은 초음파 처리 5분(생존율: 52.1%), 7분(생존율: 51.5%), 10분(생존율: 49.9%)에서 높은 생존율을 보였고. 5분간 초음파를 처리한 실험군이 가속 조건에서 가장 높은 생존율을 보였다.The survival rate of Bifidobacterium longum HY8001 in the experimental group with the highest survival rate was 5 minutes (survival rate: 52.1%), 7 minutes (survival rate: 51.5%), 10 minutes (survival rate: 49.9% And high survival rate. Experimental group treated with ultrasound for 5 minutes showed the highest survival rate under accelerated conditions.
<시험예 6>≪ Test Example 6 >
초음파가 복합 처리된 고시형 프로바이오틱스의 동결건조 생존율 시험Freeze-dried survival rate test of high-quality probiotics combined with ultrasound
배양 후와 코팅 후 초음파 처리된 프로바이오틱스의 동결과정에서 시험예 1 및 시험예 3의 가장 높은 생존율을 보인 초음파 처리 조건(5분, 100Hz)에서의 프로바이오틱스의 생존율을 확인하기 위하여 상기 실시예 3의 방법으로 제조된 프로바이오틱스의 동결건조 생존율을 계산하였다.In order to confirm the survival rate of probiotics under ultrasound treatment conditions (5 min, 100 Hz) showing the highest survival rate in Test Example 1 and Test Example 3 in the freezing process of the ultrasonic treated probiotics after culturing and coating, Freeze-dried survival rate of probiotics was calculated.
상기 '생존율'은 동결건조 후 생존균 수를 동결건조 전 생존균 수로 나눈 값의 백분율을 의미한다.The 'survival rate' means the percentage of viable cells after lyophilization divided by the number of viable cells before lyophilization.
대조군은 배양 후와 코팅 후 초음파 처리가 되지 않은 것을 제외하고는 상기 실시예 3과 동일한 방법으로 제조된 프로바이오틱스 동결건조분말을 대상으로 하였다.The control group was a freeze-dried powder of probiotic prepared by the same method as in Example 3, except that after the incubation and after the coating, the ultrasonic treatment was not performed.
그 결과를 하기의 표 7에 나타내었다.The results are shown in Table 7 below.
표 7에서 확인할 수 있는 바와같이, 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 생존율은 대조군의 생존율 보다 약 10% 높았고, 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 생존율은 대조군의 생존율 보다 약 10% 높았으며, 기타 고시형 프로바이오틱스들의 생존율도 대조군의 생존율 보다 높게 나타났다.As can be seen in Table 7, the survival rate of Lactobacillus plantarum HY7715 was about 10% higher than that of the control group, and the survival rate of Bifidobacterium longum HY8001 was about 10 %, And the survival rate of other prognostic probiotics was higher than the survival rate of the control group.
<시험예 7>≪ Test Example 7 >
프로바이오틱스 완제품의 유통안정성 시험Distribution stability test of probiotics finished product
프로바이오틱스 완제품의 유통과정에서의 안정성을 확인하기 위하여 상기 실시예 1 내지 3의 각각의 프로바이오틱스 동결건조분말 10중량부에 식이섬유 35중량부, 올리고당 10중량부, 향미분말 25중량부 및 유당혼합분말 10중량부를 첨가하여 고속회전 혼합기에서 완전 혼합한 후 스틱포장하여 제조한 완제품을 냉장(10℃ 이하, 습도 40% 이하) , 상온(25℃, 습도 40~60%) 및 가속(40℃, 습도 70%)의 조건에서 6개월 보관 후 프로바이오틱스의 생존율을 계산하였다.In order to confirm the stability in the circulation process of the finished probiotics, 35 parts by weight of dietary fiber, 10 parts by weight of oligosaccharide, 25 parts by weight of flavor powder and 10 parts by weight of lactose mixed powder 10 were mixed with 10 parts by weight of lyophilized powder of each of the probiotics of Examples 1 to 3, (25 ° C., humidity: 40 to 60%) and accelerated (40 ° C., humidity: 70 ° C., humidity: 40% or less) %) For 6 months. The survival rate of probiotics was calculated.
상기 '생존율'은 유통안정성 시험 후 생존균 수를 유통안정성 시험 전 생존균 수로 나눈 값의 백분율을 의미한다.The 'survival rate' means the percentage of viable cell count after distribution stability test divided by viable cell count before circulating stability test.
대조군은 초음파 처리가 되지 않은 것을 제외하고는 상기 실시예 1 내지 3과 동일한 방법으로 제조된 프로바이오틱스 동결건조분말을 사용하여 제조한 완제품을 사용한 것을 제외하고는 상기와 동일한 방법으로 시험하였다.Control groups were tested in the same manner as described above, except that the final product prepared using the freeze-dried powder of probiotics prepared in the same manner as in Examples 1 to 3 was used, except that the ultrasonic treatment was not performed.
그 결과를 하기의 표 8(냉장 조건), 표 9(상온 조건) 및 표 10(가속 조건)에 나타내었다.The results are shown in Table 8 below (refrigeration conditions), Table 9 (room temperature conditions) and Table 10 (acceleration conditions).
하기의 표 8 내지 표 10에서 확인할 수 있는 바와 같이, ①냉장보관의 경우의 생존율은 대조군과 실시예 1 내지 3은 크게 차이가 발생하지 않았으나, ②상온보관의 경우에는 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 생존율은 대조군의 생존율 보다 약 13 내지 15% 높았고, 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 생존율은 대조군의 생존율 보다 약 13 내지 15% 높았으며, 기타 프로바이오틱스들의 생존율도 대조군의 생존율 보다 높게 나타났고, ③가속보관의 경우에는 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 생존율은 대조군의 생존율 보다 약 15 내지 16% 높았고, 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 생존율은 대조군의 생존율 보다 약 15 내지 16% 높았으며, 기타 고시형 프로바이오틱스들의 생존율도 대조군의 생존율 보다 높게 나타났다.As can be seen from the following Tables 8 to 10, the survival rate in the case of refrigerated storage was not significantly different from that in the control group and in Examples 1 to 3. However, in the case of storage at room temperature, the survival rate of Lactobacillus plantarum HY7715 was about 13 to 15% higher than that of the control group, and the survival rate of Bifidobacterium longum HY8001 was about 13 to 15% higher than that of the control group. The survival rate of other probiotics was also higher than that of the control group And the survival rate of Lactobacillus plantarum HY7715 was about 15 to 16% higher than that of the control group in the case of accelerated storage and the survival rate of Bifidobacterium longum HY8001 was higher than that of the control group Survival rate was about 15 to 16% higher than other survival rates, and the survival rate of other prognostic probiotics was also higher in the survival rate Respectively.
<시험예 8><Test Example 8>
프로바이오틱스의 소화관 생존율 시험Probiotics survival rate test of probiotics
8-1. 프로바이오틱스 시료의 제조 8-1. Preparation of probiotic samples
상기 실시예 1 내지 3의 프로바이오틱스 동결건조분말을 최종 농도가 1x109cfu/ml이 되도록 PBS 완충용액에 용해하였다.The lyophilized powder of probiotics of Examples 1 to 3 was dissolved in PBS buffer to a final concentration of 1 x 10 9 cfu / ml.
8-2. 전해질 용액의 제조 8-2. Preparation of Electrolyte Solution
A standardised static in vitro digestion method suitable for food?? an international consensus (M. Minekus et al. Food Funct. 2014 (5) : 1113-1124) 등의 논문에 사용된 실험법을 참고하여 소화모델에 사용되는 전해질 용액을 하기의 표 11과 같이 제조하였다.A standardized static in vitro digestion method suitable for food? an international consensus (M. Minekus et al., Food Funct. 2014 (5): 1113-1124) was prepared as shown in Table 11 below.
(SGF, mmol/L)Simulated Gastric Fluid
(SGF, mmol / L)
(SIF, mmol/L)Simulated Intestinal Fluid
(SIF, mmol / L)
8-3. 소화관 생존율의 측정 8-3. Measurement of survival rate of digestive tract
구강 단계에서는 상기 실시예 8-1에서 제조한 프로바이오틱스 시료에 상기 표 11의 SSF(Simulated Salivary Fluid) 전해질 용액 및 인체유래 타액의 알파-아밀라제(α-amylase)를 첨가하여 37℃에서 2분간 반응시켰다.In the oral phase, SSF (Simulated Salivary Fluid) electrolyte solution of Table 11 and α-amylase of saliva derived from human body were added to the probiotic sample prepared in Example 8-1 and reacted at 37 ° C for 2 minutes .
위(胃) 단계에서는 상기 구강 단계에서 소화된 시료에 상기 표 11의 SGF(Simulated Gastric Fluid) 전해질 용액과 돼지유래 펩신을 첨가하고 pH3.0으로 조절하여 37℃에서 2시간 동안 반응시켰다. In the stomach, the SGF (Simulated Gastric Fluid) electrolyte solution and the pepsin-derived pepsin of Table 11 were added to the digested sample at the oral stage, and the pH was adjusted to 3.0, followed by reaction at 37 ° C for 2 hours.
소장단계에서는 상기 위(胃) 단계에서 소화된 시료에 돼지유래 판크레아틴 및 담즙산을 첨가하여 pH7.0으로 조절한 뒤 37℃에서 2시간 동안 반응시켰다. In the small intestine stage, porcine derived pancreatin and bile acid were added to digested samples in the stomach, adjusted to pH 7.0, and reacted at 37 ° C for 2 hours.
마지막 흡수 단계에서는 상기 소장단계에서 소화된 시료에 자연막소포(Brush Border Membrane Vesicles)을 첨가하고 pH7.0으로 조절한 뒤 37℃에서 4시간 동안 반응시켰다.In the final absorption step, Brush Border Membrane Vesicles were added to the digested samples in the small intestine, adjusted to pH 7.0, and reacted at 37 ° C for 4 hours.
상기 모든 소화흡수 과정을 거친 후에 잔존하는 프로바이오틱스 수는 통상적인 프로바이오틱스 생균수 측정방법에 따라 생균수를 분석하였으며, 균주의 소화관 생존율은 소화흡수 전의 초기 균수와 대비하여 생존율(%)로 표현하였다.The viable counts of the probiotics remaining after the digestion and absorption process were analyzed according to a conventional method for measuring viable count of probiotics. The survival rate of the strains was expressed as survival rate (%) as compared with the initial number of bacteria before digestion and absorption.
대조군은 초음파 처리가 되지 않은 것을 제외하고는 상기 실시예 1 내지 3과 동일한 방법으로 제조된 프로바이오틱스 동결건조분말을 사용한 것을 제외하고는 상기와 동일한 방법으로 시험하였다.The control group was tested in the same manner as above except that the lyophilized powder of probiotics prepared in the same manner as in Examples 1 to 3 was used, except that the lyophilized powder was not subjected to ultrasonic treatment.
그 결과를 하기의 표 12에 나타내었다.The results are shown in Table 12 below.
하기의 표 12에서 확인할 수 있는 바와 같이, 락토바실러스 플란타룸(Lactobacillus plantarum) HY7715의 소화관 생존율은 대조군의 생존율 보다 4%(실시예 1), 7%(실시예 2), 9%(실시예 3) 높았고, 비피도박테리움 롱검(Bifidobacterium longum) HY8001의 소화관 생존율은 대조군의 생존율 보다 8%(실시예 1), 14%(실시예 2), 13%(실시예 3) 높았으며, 기타 고시형 프로바이오틱스들의 소화관 생존율도 대조군의 생존율 보다 높게 나타났다.As shown in Table 12 below, the survival rate of the digestive tract of Lactobacillus plantarum HY7715 was 4% (Example 1), 7% (Example 2) and 9% (Example 3). The survival rate of the digestive tract of Bifidobacterium longum HY8001 was higher than that of the control group by 8% (Example 1), 14% (Example 2) and 13% (Example 3) The survival rate of the gut probiotics was higher than that of the control group.
Claims (7)
(b)상기 (a)단계의 초음파 처리된 프로바이오틱스 배양액을 농축하여 프로바이오틱스 농축액을 제조하는 단계;
(c)상기 (b)단계의 프로바이오틱스 농축액에 코팅제를 첨가하는 단계; 및
(d)상기 (c)단계의 프로바이오틱스 농축액을 동결건조하는 단계를 포함하며,
상기 프로바이오틱스(Probiotics)는 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 가세리(Lactobacillus gasseri), 락토바실러스 델부르키 에스에스피 불가리쿠스(Lactobacillus delbrueckii ssp. bulgaricus), 락토바실러스 헬베티쿠스(Lactobacillus helveticus), 락토바실러스 퍼멘텀(Lactobacillus fermentum), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 루테리(Lactobacillus reuteri), 락토코커스 락티스(Lactococcus lactis), 스트렙토코커스 써모필러스(Streptococcus thermophilus), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 비피덤(Bifidobacterium bifidum), 비피도박테리움 브레베(Bifidobacterium breve), 비피도박테리움 에니멀리스 에스에스피 락티스(Bifidobacterium animalis ssp. lactis) 중 어느 하나인 것을 특징으로 하는 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법.
(a) treating ultrasound in a culture medium of Probiotics for 5 minutes at a condition of 100 Hz;
(b) concentrating the ultrasound-treated probiotic culture solution of step (a) to prepare a probiotic concentrate;
(c) adding a coating agent to the probiotic concentrate of step (b); And
(d) lyophilizing the probiotic concentrate of step (c)
The probiotics may be selected from the group consisting of Lactobacillus plantarum , Lactobacillus acidophilus , Lactobacillus casei , Lactobacillus gasseri , Lactobacillus delbrueckii , eseueseu blood Bulgaria kusu (Lactobacillus delbrueckii ssp. bulgaricus), Lactobacillus helveticus (Lactobacillus helveticus), Lactobacillus buffer momentum (Lactobacillus fermentum), Lactobacillus para casei (Lactobacillus paracasei), Lactobacillus ramno suspension (Lactobacillus rhamnosus), Lactobacillus reuteri , Lactococcus lactis , Streptococcus thermophilus , Bifidobacterium longum , Bifidobacterium bifidum , Bifidobacterium bifidum , Bifidobacterium bifidum , Bifidobacterium bifidum , Te Solarium breve (Bifidobacterium breve), BP gambling Terry Enimeol less eseueseu blood lactis (Bifidobacterium animalis ssp. Lactis) a method of increasing the reliability, and any one of the coating efficiency of the probiotics, characterized in that one.
(b)상기 (a)단계의 프로바이오틱스 농축액에 코팅제를 첨가하면서 초음파를 5분 동안 100Hz 조건으로 처리하는 단계; 및
(c)상기 (b)단계의 초음파 처리된 프로바이오틱스 농축액을 동결건조하는 단계를 포함하며,
상기 프로바이오틱스(Probiotics)는 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 가세리(Lactobacillus gasseri), 락토바실러스 델부르키 에스에스피 불가리쿠스(Lactobacillus delbrueckii ssp. bulgaricus), 락토바실러스 헬베티쿠스(Lactobacillus helveticus), 락토바실러스 퍼멘텀(Lactobacillus fermentum), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 루테리(Lactobacillus reuteri), 락토코커스 락티스(Lactococcus lactis), 스트렙토코커스 써모필러스(Streptococcus thermophilus), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 비피덤(Bifidobacterium bifidum), 비피도박테리움 브레베(Bifidobacterium breve), 비피도박테리움 에니멀리스 에스에스피 락티스(Bifidobacterium animalis ssp. lactis) 중 어느 하나인 것을 특징으로 하는 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법.
(a) preparing a probiotic concentrate by concentrating a culture of probiotics;
(b) treating ultrasound for 5 minutes at 100 Hz condition while adding a coating agent to the probiotic concentrate of step (a); And
(c) lyophilizing the ultrasound-treated probiotic concentrate of step (b)
The probiotics may be selected from the group consisting of Lactobacillus plantarum , Lactobacillus acidophilus , Lactobacillus casei , Lactobacillus gasseri , Lactobacillus delbrueckii , eseueseu blood Bulgaria kusu (Lactobacillus delbrueckii ssp. bulgaricus), Lactobacillus helveticus (Lactobacillus helveticus), Lactobacillus buffer momentum (Lactobacillus fermentum), Lactobacillus para casei (Lactobacillus paracasei), Lactobacillus ramno suspension (Lactobacillus rhamnosus), Lactobacillus reuteri , Lactococcus lactis , Streptococcus thermophilus , Bifidobacterium longum , Bifidobacterium bifidum , Bifidobacterium bifidum , Bifidobacterium bifidum , Bifidobacterium bifidum , Te Solarium breve (Bifidobacterium breve), BP gambling Terry Enimeol less eseueseu blood lactis (Bifidobacterium animalis ssp. Lactis) a method of increasing the reliability, and any one of the coating efficiency of the probiotics, characterized in that one.
(b)상기 (a)단계의 초음파 처리된 프로바이오틱스 배양액을 농축하여 프로바이오틱스 농축액을 제조하는 단계;
(c)상기 (b)단계의 프로바이오틱스 농축액에 코팅제를 첨가하면서 초음파를 5분 동안 100Hz 조건으로 처리하는 단계; 및
(d)상기 (c)단계의 초음파 처리된 프로바이오틱스 농축액을 동결건조하는 단계를 포함하며,
상기 프로바이오틱스(Probiotics)는 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 가세리(Lactobacillus gasseri), 락토바실러스 델부르키 에스에스피 불가리쿠스(Lactobacillus delbrueckii ssp. bulgaricus), 락토바실러스 헬베티쿠스(Lactobacillus helveticus), 락토바실러스 퍼멘텀(Lactobacillus fermentum), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 루테리(Lactobacillus reuteri), 락토코커스 락티스(Lactococcus lactis), 스트렙토코커스 써모필러스(Streptococcus thermophilus), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 비피덤(Bifidobacterium bifidum), 비피도박테리움 브레베(Bifidobacterium breve), 비피도박테리움 에니멀리스 에스에스피 락티스(Bifidobacterium animalis ssp. lactis) 중 어느 하나인 것을 특징으로 하는 프로바이오틱스의 안정성 및 코팅효율을 증가시키는 방법.
(a) treating ultrasound in a culture medium of Probiotics for 5 minutes at a condition of 100 Hz;
(b) concentrating the ultrasound-treated probiotic culture solution of step (a) to prepare a probiotic concentrate;
(c) treating ultrasound for 5 minutes at 100 Hz while adding a coating agent to the probiotic concentrate of step (b); And
(d) lyophilizing the ultrasound-treated probiotic concentrate of step (c)
The probiotics may be selected from the group consisting of Lactobacillus plantarum , Lactobacillus acidophilus , Lactobacillus casei , Lactobacillus gasseri , Lactobacillus delbrueckii , eseueseu blood Bulgaria kusu (Lactobacillus delbrueckii ssp. bulgaricus), Lactobacillus helveticus (Lactobacillus helveticus), Lactobacillus buffer momentum (Lactobacillus fermentum), Lactobacillus para casei (Lactobacillus paracasei), Lactobacillus ramno suspension (Lactobacillus rhamnosus), Lactobacillus reuteri , Lactococcus lactis , Streptococcus thermophilus , Bifidobacterium longum , Bifidobacterium bifidum , Bifidobacterium bifidum , Bifidobacterium bifidum , Bifidobacterium bifidum , Te Solarium breve (Bifidobacterium breve), BP gambling Terry Enimeol less eseueseu blood lactis (Bifidobacterium animalis ssp. Lactis) a method of increasing the reliability, and any one of the coating efficiency of the probiotics, characterized in that one.
A food composition comprising a lyophilized powder of Probiotics prepared by the method of any one of claims 1 to 3 as an active ingredient.
상기 식품조성물은 발효유, 건강기능식품, 기능성 음료 중 어느 하나인 것을 특징으로 하는 식품조성물.The method according to claim 6,
Wherein the food composition is any one of a fermented milk, a health functional food, and a functional beverage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180082927A KR101927859B1 (en) | 2018-07-17 | 2018-07-17 | Method for improving the stability and coating efficiency of probiotics using ultrasonic wave after freeze-drying and food composition containing freeze-dried powder of probiotics prepared thereby as effective component |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180082927A KR101927859B1 (en) | 2018-07-17 | 2018-07-17 | Method for improving the stability and coating efficiency of probiotics using ultrasonic wave after freeze-drying and food composition containing freeze-dried powder of probiotics prepared thereby as effective component |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101927859B1 true KR101927859B1 (en) | 2018-12-11 |
Family
ID=64671618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180082927A KR101927859B1 (en) | 2018-07-17 | 2018-07-17 | Method for improving the stability and coating efficiency of probiotics using ultrasonic wave after freeze-drying and food composition containing freeze-dried powder of probiotics prepared thereby as effective component |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101927859B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110279118A (en) * | 2019-06-14 | 2019-09-27 | 浙江大学宁波理工学院 | A kind of compound probiotic composition, compound probiotic freeze-dried powder capsule and preparation method |
KR102084350B1 (en) * | 2019-04-05 | 2020-03-03 | 에스케이바이오랜드 주식회사 | Method of preparing lava seawater mineral coating probiotics and lava seawater mineral coating probiotics thereby |
KR102133802B1 (en) * | 2020-02-14 | 2020-07-14 | 이혜경 | Meat snack composition for pet's health care and its manufacturing method |
KR102133811B1 (en) * | 2020-02-14 | 2020-07-14 | 이혜경 | Poultry meat snack composition for pet's health care and its manufacturing method |
WO2020204615A1 (en) * | 2019-04-05 | 2020-10-08 | 에스케이바이오랜드 주식회사 | Method for producing lava seawater-derived natural mineral-coated probiotics and lava seawater-derived natural mineral-coated probiotics using same |
KR20210107435A (en) | 2020-02-24 | 2021-09-01 | 주식회사 현대바이오랜드 | Method of preparing lava seawater natural mineral coating probiotics and spray-drided formulations of lava seawater natural mineral coating probiotics thereby |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101605516B1 (en) | 2015-06-11 | 2016-03-23 | 주식회사 종근당바이오 | Method for Increasing Viability, Storage Stability, Acid Tolerance or Oxgall Tolerance of Lactic Acid Bacteria |
-
2018
- 2018-07-17 KR KR1020180082927A patent/KR101927859B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101605516B1 (en) | 2015-06-11 | 2016-03-23 | 주식회사 종근당바이오 | Method for Increasing Viability, Storage Stability, Acid Tolerance or Oxgall Tolerance of Lactic Acid Bacteria |
Non-Patent Citations (1)
Title |
---|
Ultrasonics Sonochemitry 19 (2012) 160-173. |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102084350B1 (en) * | 2019-04-05 | 2020-03-03 | 에스케이바이오랜드 주식회사 | Method of preparing lava seawater mineral coating probiotics and lava seawater mineral coating probiotics thereby |
WO2020204615A1 (en) * | 2019-04-05 | 2020-10-08 | 에스케이바이오랜드 주식회사 | Method for producing lava seawater-derived natural mineral-coated probiotics and lava seawater-derived natural mineral-coated probiotics using same |
CN110279118A (en) * | 2019-06-14 | 2019-09-27 | 浙江大学宁波理工学院 | A kind of compound probiotic composition, compound probiotic freeze-dried powder capsule and preparation method |
KR102133802B1 (en) * | 2020-02-14 | 2020-07-14 | 이혜경 | Meat snack composition for pet's health care and its manufacturing method |
KR102133811B1 (en) * | 2020-02-14 | 2020-07-14 | 이혜경 | Poultry meat snack composition for pet's health care and its manufacturing method |
KR20210107435A (en) | 2020-02-24 | 2021-09-01 | 주식회사 현대바이오랜드 | Method of preparing lava seawater natural mineral coating probiotics and spray-drided formulations of lava seawater natural mineral coating probiotics thereby |
KR102305076B1 (en) | 2020-02-24 | 2021-09-24 | 주식회사 현대바이오랜드 | Method of preparing lava seawater natural mineral coating probiotics and spray-drided formulations of lava seawater natural mineral coating probiotics thereby |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101927859B1 (en) | Method for improving the stability and coating efficiency of probiotics using ultrasonic wave after freeze-drying and food composition containing freeze-dried powder of probiotics prepared thereby as effective component | |
Gao et al. | Probiotics in the dairy industry—Advances and opportunities | |
Ranadheera et al. | In vitro analysis of gastrointestinal tolerance and intestinal cell adhesion of probiotics in goat's milk ice cream and yogurt | |
Soccol et al. | The potential of probiotics: a review. | |
Vasiljevic et al. | Probiotics—from Metchnikoff to bioactives | |
Marshall | Starter cultures for milk fermentation and their characteristics | |
KR101307864B1 (en) | Novel bacterium belonging to the genus bifidobacterium and utilization of the same | |
AU2006253588B2 (en) | Fermented food containing bifidobacterium bacteria and method for producing the same | |
CN109929779A (en) | A kind of probiotics preparation and its preparation method and application containing biologically active peptide | |
Solomon et al. | Substantiation of the technology for fermented sour-milk desserts with bifidogenic properties | |
ES2409854T3 (en) | Procedure to produce fermented milk | |
Araújo et al. | Probiotics in dairy fermented products | |
Hossain et al. | Impact of encapsulating probiotics with cocoa powder on the viability of probiotics during chocolate processing, storage, and in vitro gastrointestinal digestion | |
RU2451067C2 (en) | Method for enhancement of bifidobacteria viability in the process of fermented food product storage | |
CN109022323A (en) | A kind of Lactobacillus helveticus complexing agent and its preparation method and application | |
Soliman et al. | Characteristics of fermented camel’s milk fortified with kiwi or avocado fruits | |
RU2720983C2 (en) | Methods for preparation of fermented products including bifidobacteria | |
CN109715784A (en) | Bacterium | |
JP2019187251A (en) | Method for producing fermentation product and fermentation product | |
KR102273663B1 (en) | Coated probiotics, and food composition comprising the same and method for preparing thereof | |
RU2273662C2 (en) | Consortium of microorganisms with probiotic effect | |
CN109258899A (en) | A kind of nougat and preparation method thereof rich in active probiotic | |
WO2018230585A1 (en) | Microbial cell-containing non-carbonated liquid food/drink, and method for improving dispersibility of precipitates or agglomerates of microbial cell powder in food/drink | |
Kilic | The effects of probiotic cultures in functional foods: Technological aspects of probiotics | |
CN110279118A (en) | A kind of compound probiotic composition, compound probiotic freeze-dried powder capsule and preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |